Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB806 vs Simponi AstraZeneca plus methotrexate in moderate to severe rheumatoid arthritis
ChiCTR2500105364Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Jul 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CMAB806 in rheumatoid arthritis (RA) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: ACR20 response at week 24. Started Jul 2025; status: completed.
02
Drugs
CMAB806
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500105364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105364.